Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
- Gain Therapeutics is expected to deliver a year-over-year increase in earnings on flat revenues. - The consensus EPS estimate has been revised 32% lower over the last 30 days. - Gain Therapeutics doesn't appear a compelling earnings-beat candidate. - OptiNose is expected to post a loss for the quarter with an Earnings ESP of -6.46%. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Research Analysis
View signal analysis